SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives | Cardiovascular Diabetology
Zinman B, et al. Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. Empagliflozin.
Google Scholar
Mahaffey KW, et al. Canagliflozin for primary and Secondary Prevention of Cardiovascular Events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137:323–34. https://doi.org/10.1161/CIRCULATIONAHA.117.032038.
Google Scholar
Wiviott SD, et al. Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57. https://doi.org/10.1056/NEJMoa1812389.
Google Scholar
Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46. https://doi.org/10.1056/NEJMoa2024816.
Google Scholar
Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19:98. https://doi.org/10.1186/s12933-020-01071-y.
Google Scholar
Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20:479–87. https://doi.org/10.1111/dom.13126.
Google Scholar
Zaawari A, Sahar AN. Sodium-glucose co-transporter-2 inhibitors (SGLT2I): a class of drugs with promising cardiorenal protective effects beyond glycemic control. Ann Med Surg (Lond). 2022;81:104536. https://doi.org/10.1016/j.amsu.2022.104536.
Google Scholar
Leccisotti L, et al. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovasc Diabetol. 2022;21:173. https://doi.org/10.1186/s12933-022-01607-4.
Google Scholar
Cinti F, et al. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. 2023;22:349. https://doi.org/10.1186/s12933-023-02091-0.
Google Scholar
Sorice GP, et al. Effect of Dapagliflozin on myocardial insulin sensitivity and perfusion: Rationale and Design of the DAPAHEART Trial. Diabetes Ther. 2021;12:2101–13. https://doi.org/10.1007/s13300-021-01083-1.
Google Scholar
Li L, et al. SGLT2i alleviates epicardial adipose tissue inflammation by modulating ketone body-glyceraldehyde-3-phosphate dehydrogenase malonylation pathway. J Cardiovasc Med (Hagerstown). 2023;24:232–43. https://doi.org/10.2459/JCM.0000000000001453.
Google Scholar
Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542:177–85. https://doi.org/10.1038/nature21363.
Google Scholar
The L. Treating obesity and diabetes: drugs alone are not enough. Lancet. 2024;403:1. https://doi.org/10.1016/S0140-6736(24)00003-5.
Google Scholar
Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024. https://doi.org/10.1038/s41366-024-01473-y.
Google Scholar
Caruso I, et al. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine. 2023;64:102181. https://doi.org/10.1016/j.eclinm.2023.102181.
Google Scholar
Padda IS, Mahtani AU, Parmar M. in StatPearls (2024).
Jiang M, Steyger PS. An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus. Expert Opin Ther Pat. 2015;25:1349–52. https://doi.org/10.1517/13543776.2015.1076392.
Google Scholar
Giugliano D, et al. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021;20:236. https://doi.org/10.1186/s12933-021-01430-3.
Google Scholar
Davies MJ, et al. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol. 2022;21:144. https://doi.org/10.1186/s12933-022-01575-9.
Google Scholar
Gao M, et al. SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and Meta-analysis. JAMA Netw Open. 2024;7:e245135. https://doi.org/10.1001/jamanetworkopen.2024.5135.
Google Scholar
Vallon V. State-of-the-art-review mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens. 2024. https://doi.org/10.1093/ajh/hpae092.
Google Scholar
Ferrannini G, et al. Energy Balance after Sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730–5. https://doi.org/10.2337/dc15-0355.
Google Scholar
Giordano A, et al. The adipose organ is a Unitary structure in mice and humans. Biomedicines. 2022;10. https://doi.org/10.3390/biomedicines10092275.
Cinti S. Pink adipocytes. Trends Endocrinol Metab. 2018;29:651–66. https://doi.org/10.1016/j.tem.2018.05.007.
Google Scholar
Cinti S. Adipose Organ Development and Remodeling. Compr Physiol. 2018;8:1357–431. https://doi.org/10.1002/cphy.c170042.
Google Scholar
Zhang Y, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32. https://doi.org/10.1038/372425a0.
Google Scholar
Duerrschmid C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23:1444–53. https://doi.org/10.1038/nm.4432.
Google Scholar
Frontini A, et al. Thymus uncoupling protein 1 is exclusive to typical brown adipocytes and is not found in thymocytes. J Histochem Cytochem. 2007;55:183–9. https://doi.org/10.1369/jhc.6A7013.2006.
Google Scholar
Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84:277–359. https://doi.org/10.1152/physrev.00015.2003.
Google Scholar
Giralt M, Cereijo R, Villarroya F. Adipokines and the endocrine role of adipose tissues. Handb Exp Pharmacol. 2016;233:265–82. https://doi.org/10.1007/164_2015_6.
Google Scholar
Barbatelli G, et al. The emergence of cold-induced brown adipocytes in mouse white fat depots is determined predominantly by white to brown adipocyte transdifferentiation. Am J Physiol Endocrinol Metab. 2010;298:E1244–1253. https://doi.org/10.1152/ajpendo.00600.2009.
Google Scholar
Frontini A, et al. White-to-brown transdifferentiation of omental adipocytes in patients affected by pheochromocytoma. Biochim Biophys Acta. 2013;1831:950–9. https://doi.org/10.1016/j.bbalip.2013.02.005.
Google Scholar
Ronkainen J, et al. Fto-Deficiency affects the gene and MicroRNA expression involved in Brown Adipogenesis and Browning of White Adipose tissue in mice. Int J Mol Sci. 2016;17. https://doi.org/10.3390/ijms17111851.
Osataphan S, et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. JCI Insight. 2019;4. https://doi.org/10.1172/jci.insight.123130.
Sacks HS, et al. Adult epicardial fat exhibits beige features. J Clin Endocrinol Metab. 2013;98:E1448–1455. https://doi.org/10.1210/jc.2013-1265.
Google Scholar
Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell. 2014;156:20–44. https://doi.org/10.1016/j.cell.2013.12.012.
Google Scholar
Barbera MJ, et al. Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J Biol Chem. 2001;276:1486–93. https://doi.org/10.1074/jbc.M006246200.
Google Scholar
Giordano A, Smorlesi A, Frontini A, Barbatelli G, Cinti S. White, brown and pink adipocytes: the extraordinary plasticity of the adipose organ. Eur J Endocrinol. 2014;170:R159–171. https://doi.org/10.1530/EJE-13-0945.
Google Scholar
De Matteis R, et al. Exercise as a new physiological stimulus for brown adipose tissue activity. Nutr Metab Cardiovasc Dis. 2013;23:582–90. https://doi.org/10.1016/j.numecd.2012.01.013.
Google Scholar
Bostrom P, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–8. https://doi.org/10.1038/nature10777.
Google Scholar
Ronkainen J, et al. Fat mass- and obesity-associated gene fto affects the dietary response in mouse white adipose tissue. Sci Rep. 2015;5:9233. https://doi.org/10.1038/srep09233.
Google Scholar
Yoneshiro T, Matsushita M, Saito M. Translational aspects of Brown Fat activation by Food-Derived stimulants. Handb Exp Pharmacol. 2019;251:359–79. https://doi.org/10.1007/164_2018_159.
Google Scholar
Cypess AM, et al. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab. 2015;21:33–8. https://doi.org/10.1016/j.cmet.2014.12.009.
Google Scholar
Gavalda-Navarro A, Villarroya J, Cereijo R, Giralt M, Villarroya F. The endocrine role of brown adipose tissue: an update on actors and actions. Rev Endocr Metab Disord. 2022;23:31–41. https://doi.org/10.1007/s11154-021-09640-6.
Google Scholar
Armani A, et al. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J. 2014;28:3745–57. https://doi.org/10.1096/fj.13-245415.
Google Scholar
Marzolla V, et al. The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol Cell Endocrinol. 2012;350:281–8. https://doi.org/10.1016/j.mce.2011.09.011.
Google Scholar
Mammi C, et al. A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet. Int J Obes (Lond). 2016;40:964–72. https://doi.org/10.1038/ijo.2016.13.
Google Scholar
Ni B, Farrar JS, Vaitkus JA, Celi FS. Metabolic effects of FGF-21: Thermoregulation and Beyond. Front Endocrinol (Lausanne). 2015;6:148. https://doi.org/10.3389/fendo.2015.00148.
Google Scholar
Giordano A, Frontini A, Cinti S. Convertible visceral fat as a therapeutic target to curb obesity. Nat Rev Drug Discov. 2016;15:405–24. https://doi.org/10.1038/nrd.2016.31.
Google Scholar
Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 1956;4:20–34. https://doi.org/10.1093/ajcn/4.1.20.
Google Scholar
Bowman K, et al. Central adiposity and the overweight risk paradox in aging: follow-up of 130,473 UK Biobank participants. Am J Clin Nutr. 2017;106:130–5. https://doi.org/10.3945/ajcn.116.147157.
Google Scholar
Guglielmi V, et al. Omental adipose tissue fibrosis and insulin resistance in severe obesity. Nutr Diabetes. 2015;5:e175. https://doi.org/10.1038/nutd.2015.22.
Google Scholar
Oikonomou EK, Antoniades C. The role of adipose tissue in cardiovascular health and disease. Nat Rev Cardiol. 2019;16:83–99. https://doi.org/10.1038/s41569-018-0097-6.
Google Scholar
Badi I, et al. Editorial: exploring the Crosstalk between adipose tissue and the Cardiovascular System. Front Cell Dev Biol. 2022;10:973135. https://doi.org/10.3389/fcell.2022.973135.
Google Scholar
Akoumianakis I, Antoniades C. The interplay between adipose tissue and the cardiovascular system: is fat always bad? Cardiovasc Res. 2017;113:999–1008. https://doi.org/10.1093/cvr/cvx111.
Google Scholar
Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19:593–606. https://doi.org/10.1038/s41569-022-00679-9.
Google Scholar
Marchington JM, Mattacks CA, Pond CM. Adipose tissue in the mammalian heart and pericardium: structure, foetal development and biochemical properties. Comp Biochem Physiol B. 1989;94:225–32. https://doi.org/10.1016/0305-0491(89)90337-4.
Google Scholar
Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22:450–7. https://doi.org/10.1016/j.tem.2011.07.003.
Google Scholar
Carena MC, et al. Role of human epicardial adipose tissue-derived miR-92a-3p in myocardial redox state. J Am Coll Cardiol. 2023;82:317–32. https://doi.org/10.1016/j.jacc.2023.05.031.
Google Scholar
Badi I, Antoniades C. Brown Adipose tissue and the take (12,13-di)HOME Message to the heart. Circulation. 2021;143:160–2. https://doi.org/10.1161/CIRCULATIONAHA.120.051981.
Google Scholar
Pinckard KM, et al. A novel endocrine role for the BAT-Released lipokine 12,13-diHOME to Mediate Cardiac function. Circulation. 2021;143:145–59. https://doi.org/10.1161/CIRCULATIONAHA.120.049813.
Google Scholar
Mazurek T, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:2460–6. https://doi.org/10.1161/01.CIR.0000099542.57313.C5.
Google Scholar
Li Y, et al. Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol. 2019;18:3. https://doi.org/10.1186/s12933-019-0807-3.
Google Scholar
Malavazos AE, et al. The density of crown-like structures in epicardial adipose tissue could play a role in cardiovascular diseases. Eat Weight Disord. 2022;27:2905–10. https://doi.org/10.1007/s40519-022-01420-8.
Google Scholar
Weisberg SP, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–808. https://doi.org/10.1172/JCI19246.
Google Scholar
Kotzbeck P, et al. Brown adipose tissue whitening leads to brown adipocyte death and adipose tissue inflammation. J Lipid Res. 2018;59:784–94. https://doi.org/10.1194/jlr.M079665.
Google Scholar
Valori C, Thomas M, Shillingford J. Free noradrenaline and adrenaline excretion in relation to clinical syndromes following myocardial infarction. Am J Cardiol. 1967;20:605–17. https://doi.org/10.1016/0002-9149(67)90001-x.
Google Scholar
Wang L, et al. Cardiac ischemia modulates white adipose tissue in a depot-specific manner. Front Physiol. 2022;13:1036945. https://doi.org/10.3389/fphys.2022.1036945.
Google Scholar
Cypess AM, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360:1509–17. https://doi.org/10.1056/NEJMoa0810780.
Google Scholar
Tam CS, Lecoultre V, Ravussin E. Brown adipose tissue: mechanisms and potential therapeutic targets. Circulation. 2012;125:2782–91. https://doi.org/10.1161/CIRCULATIONAHA.111.042929.
Google Scholar
Becher T, et al. Brown adipose tissue is associated with cardiometabolic health. Nat Med. 2021;27:58–65. https://doi.org/10.1038/s41591-020-1126-7.
Google Scholar
Valenzuela PL, et al. Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol. 2023;20:475–94. https://doi.org/10.1038/s41569-023-00847-5.
Google Scholar
Antoniades C, et al. Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers. Eur Heart J. 2023. https://doi.org/10.1093/eurheartj/ehad484.
Google Scholar
Iacobellis G, Baroni MG. Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. J Endocrinol Invest. 2022;45:489–95. https://doi.org/10.1007/s40618-021-01687-1.
Google Scholar
Capece U, et al. Dapagliflozin-Induced myocardial Flow Reserve Improvement is not Associated with HDL ability to stimulate endothelial nitric oxide production. Diabetes Ther. 2023. https://doi.org/10.1007/s13300-023-01491-5.
Google Scholar
Santos-Gallego CG, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73:1931–44. https://doi.org/10.1016/j.jacc.2019.01.056.
Google Scholar
Santos-Gallego CG, Mayr M, Badimon J. SGLT2 inhibitors in Heart failure: targeted metabolomics and energetic metabolism. Circulation. 2022;146:819–21. https://doi.org/10.1161/CIRCULATIONAHA.122.060805.
Google Scholar
Nishitani S, et al. Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes. Sci Rep. 2018;8:8805. https://doi.org/10.1038/s41598-018-27181-y.
Google Scholar
Youssef ME, et al. Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond Glycemic Control. Int J Mol Sci. 2023;24. https://doi.org/10.3390/ijms24076039.
Miyachi Y, et al. A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition. Sci Rep. 2018;8:16113. https://doi.org/10.1038/s41598-018-34305-x.
Google Scholar
Hui X, et al. Adiponectin enhances Cold-Induced Browning of Subcutaneous Adipose tissue via promoting M2 macrophage proliferation. Cell Metab. 2015;22:279–90. https://doi.org/10.1016/j.cmet.2015.06.004.
Google Scholar
Pruett JE, et al. Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition. Biol Sex Differ. 2022;13:45. https://doi.org/10.1186/s13293-022-00455-x.
Google Scholar
Croteau D, et al. Effects of Sodium-glucose linked transporter 2 inhibition with ertugliflozin on mitochondrial function, energetics, and metabolic gene expression in the Presence and absence of diabetes Mellitus in mice. J Am Heart Assoc. 2021;10:e019995. https://doi.org/10.1161/JAHA.120.019995.
Google Scholar
Woods TC, et al. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and mitigates kidney Injury and Hypertension in Mouse Model of type 2 diabetes Mellitus. Am J Nephrol. 2019;49:331–42. https://doi.org/10.1159/000499597.
Google Scholar
Takagi S, et al. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J Diabetes Investig. 2018;9:1025–32. https://doi.org/10.1111/jdi.12802.
Google Scholar
Kondo H, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42:4947–60. https://doi.org/10.1093/eurheartj/ehab420.
Google Scholar
Cuevas-Ramos D, Mehta R, Aguilar-Salinas CA. Fibroblast growth factor 21 and Browning of White Adipose tissue. Front Physiol. 2019;10:37. https://doi.org/10.3389/fphys.2019.00037.
Google Scholar
Di Vincenzo A, et al. Treatment with dapagliflozin increases FGF-21 gene expression and reduces triglycerides content in myocardial tissue of genetically obese mice. J Endocrinol Invest. 2024. https://doi.org/10.1007/s40618-023-02273-3.
Google Scholar
Xiang L, et al. Dapagliflozin promotes white adipose tissue browning though regulating angiogenesis in high fat induced obese mice. BMC Pharmacol Toxicol. 2024;25:26. https://doi.org/10.1186/s40360-024-00747-5.
Google Scholar
Giaccari A. Sodium-glucose co-transporter inhibitors: medications that mimic fasting for cardiovascular prevention. Diabetes Obes Metab. 2019;21:2211–8. https://doi.org/10.1111/dom.13814.
Google Scholar
Wallenius K, et al. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic beta-oxidation, and induces ketosis. J Lipid Res. 2022;63:100176. https://doi.org/10.1016/j.jlr.2022.100176.
Google Scholar
Diaz-Rodriguez E, et al. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res. 2018;114:336–46. https://doi.org/10.1093/cvr/cvx186.
Google Scholar
Merovci A, et al. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J Clin Endocrinol Metab. 2015;100:1927–32. https://doi.org/10.1210/jc.2014-3472.
Google Scholar
Buttice L, et al. The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26:2706–21. https://doi.org/10.1111/dom.15586.
Google Scholar
Wang X, Wu N, Sun C, Jin D, Lu H. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2023;15:113. https://doi.org/10.1186/s13098-023-01085-y.
Google Scholar
Bando Y, et al. The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus. Diabetol Int. 2017;8:218–27. https://doi.org/10.1007/s13340-016-0302-y.
Google Scholar
Eriksson JW, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61:1923–34. https://doi.org/10.1007/s00125-018-4675-2.
Google Scholar
Ito D, et al. Comparison of Ipragliflozin and Pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a Randomized, 24-Week, Open-Label, active-controlled trial. Diabetes Care. 2017;40:1364–72. https://doi.org/10.2337/dc17-0518.
Google Scholar
Koshizaka M, et al. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: a prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study). Diabetes Obes Metab. 2019;21:1990–5. https://doi.org/10.1111/dom.13750.
Google Scholar
Latva-Rasku A, et al. The SGLT2 inhibitor Dapagliflozin reduces Liver Fat but does not affect tissue insulin sensitivity: a Randomized, Double-Blind, placebo-controlled study with 8-Week treatment in type 2 diabetes patients. Diabetes Care. 2019;42:931–7. https://doi.org/10.2337/dc18-1569.
Google Scholar
Inoue H, et al. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial. J Diabetes Investig. 2019;10:1012–21. https://doi.org/10.1111/jdi.12985.
Google Scholar
McCrimmon RJ, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63:473–85. https://doi.org/10.1007/s00125-019-05065-8.
Google Scholar
Han E, Lee YH, Lee BW, Kang ES, Cha BS. Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-Week randomized controlled trial. J Clin Med. 2020;9. https://doi.org/10.3390/jcm9010259.
Brown AJM, et al. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020;41:3421–32. https://doi.org/10.1093/eurheartj/ehaa419.
Google Scholar
Kinoshita T, et al. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study. J Diabetes Investig. 2020;11:1612–22. https://doi.org/10.1111/jdi.13279.
Google Scholar
Gaborit B, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol. 2021;20:57. https://doi.org/10.1186/s12933-021-01237-2.
Google Scholar
Lopaschuk GD, Verma S. Mechanisms of Cardiovascular benefits of Sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632–44. https://doi.org/10.1016/j.jacbts.2020.02.004.
Google Scholar
Preda A, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024;120:443–60. https://doi.org/10.1093/cvr/cvae047.
Google Scholar
D’Marco L et al. SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence. J Diabetes Res 2021, 9032378 (2021). https://doi.org/10.1155/2021/9032378
Ryk A, et al. Cholesin receptor signalling is active in cardiovascular system-associated adipose tissue and correlates with SGLT2i treatment in patients with diabetes. Cardiovasc Diabetol. 2024;23:211. https://doi.org/10.1186/s12933-024-02322-y.
Google Scholar
Masson W, Lavalle-Cobo A, Nogueira JP. Effect of SGLT2-Inhibitors on Epicardial Adipose tissue: a Meta-analysis. Cells. 2021;10. https://doi.org/10.3390/cells10082150.
Iacobellis G, Gra-Menendez S. Effects of Dapagliflozin on Epicardial Fat Thickness in patients with type 2 diabetes and obesity. Obes (Silver Spring). 2020;28:1068–74. https://doi.org/10.1002/oby.22798.
Google Scholar
Song XT, Wei YL, Rui YF, Fan L. Echocardiographic evaluation of the effect of dapagliflozin on epicardial adipose tissue and left ventricular systolic function in type 2 diabetes mellitus. J Diabetes Complications. 2023;37:108509. https://doi.org/10.1016/j.jdiacomp.2023.108509.
Google Scholar
Requena-Ibanez JA, et al. Not only how much, but also how to, when measuring epicardial adipose tissue. Magn Reson Imaging. 2022;86:149–51. https://doi.org/10.1016/j.mri.2021.11.004.
Google Scholar
Yagi S, et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9:78. https://doi.org/10.1186/s13098-017-0275-4.
Google Scholar
Bouchi R, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16:32. https://doi.org/10.1186/s12933-017-0516-8.
Google Scholar
Sato T, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17:6. https://doi.org/10.1186/s12933-017-0658-8.
Google Scholar
Sato T, et al. The Effect of Dapagliflozin Treatment on Epicardial Adipose tissue volume and P-Wave indices: an Ad-hoc analysis of the previous Randomized Clinical Trial. J Atheroscler Thromb. 2020;27:1348–58. https://doi.org/10.5551/jat.48009.
Google Scholar
Requena-Ibanez JA, et al. Mechanistic insights of Empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study. JACC Heart Fail. 2021;9:578–89. https://doi.org/10.1016/j.jchf.2021.04.014.
Google Scholar
Hiruma S, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol. 2021;20:32. https://doi.org/10.1186/s12933-021-01228-3.
Google Scholar
Zhao J, et al. Excessive accumulation of epicardial adipose tissue promotes microvascular obstruction formation after myocardial ischemia/reperfusion through modulating macrophages polarization. Cardiovasc Diabetol. 2024;23:236. https://doi.org/10.1186/s12933-024-02342-8.
Google Scholar
Malavazos AE, et al. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies. Eur J Prev Cardiol. 2023;30:680–93. https://doi.org/10.1093/eurjpc/zwad050.
Google Scholar
Kasperova BJ, et al. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure. Cardiovasc Diabetol. 2024;23:223. https://doi.org/10.1186/s12933-024-02298-9.
Google Scholar
Maliszewska K, Kretowski A. Brown Adipose tissue and its role in insulin and glucose homeostasis. Int J Mol Sci. 2021;22. https://doi.org/10.3390/ijms22041530.
Brown KA, Scherer PE. Update on adipose tissue and Cancer. Endocr Rev. 2023;44:961–74. https://doi.org/10.1210/endrev/bnad015.
Google Scholar
link
